MMRCS1 is caused by biallelic (homozygous or compound heterozygous) pathogenic variants in the MLH1 gene, which encodes MutL Homolog 1, an essential component of the DNA mismatch repair complex. ClinGen has assigned MLH1 a DEFINITIVE classification for this gene-disease relationship. Complete MLH1 deficiency results in constitutional MMR deficiency — meaning every cell in the body lacks functional mismatch repair capacity, sharply elevating the probability of tumor-forming mutations throughout development and childhood. The biallelic inheritance pattern distinguishes MMRCS1 from Lynch syndrome, in which one functional MLH1 copy is retained. Pathogenic variants in other MMR genes (MSH2, MSH6, PMS2) have been associated with overlapping CMMRD presentations under related MONDO entities, but this entry specifically designates MLH1-related MMRCS1.

Diagnosis of MMRCS1 is established through molecular genetic testing demonstrating biallelic pathogenic variants in MLH1. Clinical suspicion typically arises in pediatric patients presenting with brain tumors combined with café-au-lait macules, gastrointestinal polyposis, or other hallmark features. Immunohistochemistry for MMR protein expression on tumor tissue can reveal absent MLH1 staining, serving as a useful initial diagnostic indicator. Microsatellite instability testing and constitutional MMR deficiency (CMMRD) screening tools have been developed to guide clinical evaluation and molecular workup in at-risk individuals. Genetic evaluation of parents may reveal heterozygous pathogenic MLH1 variants consistent with Lynch syndrome carrier status, providing important family context.

No approved pharmacologic treatments specific to MMRCS1 are documented in this packet. Cancer management in MMRCS1 follows oncology protocols appropriate to each specific tumor type and stage encountered. The high MMR-deficiency (dMMR) and microsatellite instability-high (MSI-H) status of MMRCS1-associated tumors has generated research interest in immune checkpoint inhibitors, which have shown activity in dMMR/MSI-H cancers in broader oncology contexts. Active and recruiting clinical trials registered with ClinicalTrials.gov are evaluating immunotherapy approaches including pembrolizumab and other checkpoint-directed agents across dMMR solid tumors, pediatric brain tumors, and MSI-H colorectal cancer — several of which may enroll individuals with MMRCS1-associated tumors.

Prognosis in MMRCS1 is significantly impacted by the early onset and multiplicity of malignancies. The condition is associated with a high tumor burden beginning in childhood, with multiple cancer types potentially arising across the lifespan. Specific survival statistics are not available in this packet. The broad tumor spectrum — from hematologic malignancies to high-grade gliomas — means prognosis varies substantially depending on which tumors manifest and at what stage they are identified. The high MSI-H status of MMRCS1-associated tumors may influence response to immunotherapeutic interventions, a question under active clinical investigation.

Several active and recruiting clinical trials are registered with ClinicalTrials.gov that are relevant to MMRCS1-associated malignancies. Studies are evaluating immunotherapy regimens (including pembrolizumab) for pediatric and adult brain tumors with mismatch repair deficiency, dMMR colorectal cancer, and advanced solid tumors with MSI-H status. Additionally, familial cancer predisposition registries are actively enrolling participants with childhood cancer predisposition syndromes, providing longitudinal data on natural history and outcomes. Research interest in MMRCS1 has grown with broader recognition of the oncologic significance of MMR deficiency and the potential therapeutic utility of checkpoint immunotherapy in this context.